Acadia Pharmaceuticals | ACAD - Current Liabilities


Acadia Pharmaceuticals reported $332.22M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
ALKERMES USD 651.93M 10.16M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Bristol-Myers Squibb USD 18.75B 94M Sep/2026
Cara Therapeutics USD 8.08M 3.18M Sep/2026
Corcept Therapeutics USD 177.68M 23.87M Sep/2026
Cytokinetics USD 353.42M 171.99M Sep/2026
Eisai JPY 371.5B 22.14B Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Incyte USD 1.44B 125.72M Sep/2026
J&J USD 55.46B 562M Sep/2026
Moderna USD 2.03B 506M Sep/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Pfizer USD 31.73B 920M Sep/2026
Prothena USD 11.43M 224K Sep/2026
PTC Therapeutics USD 776.08M 5.01M Sep/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026